Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Portugal

Marie Skłodowska-Curie Action · Running

GlyCaBiota Doctoral Training Network on Glycan–Cancer–Microbiota Interactions for Therapeutic and Diagnostic Innovation in Colorectal cancer

Coordinator
Universidade Nova De Lisboa, Portugal
Runs
1 January 2027 to 31 December 2030
Status
Running
EU funding
€4.7m
Total cost
—
Partners
20 organisations in 9 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101312796

What the project is doing

In the project's own words, from its summary on CORDIS.

Colorectal cancer (CRC) remains a major global health challenge, and increasing evidence shows that gut microbiota plays a decisive role in tumour progression and immune escape. Yet, the molecular rules governing communication between tumour cells, microbes and the immune system remain unknown. GlyCaBiota DN addresses this critical gap by focusing on how tumour and microbial glycans and proteins that recognize them shape CRC biology.

Our innovative programme places glycan-mediated interactions at the core of the tumour–microbiota–immune axis, enabling the rational development of next-generation diagnostic and therapeutic strategies. By combining structural, cellular and computational approaches, GlyCaBiota will decode the molecular mechanisms driving microbial colonisation, immune modulation and CRC progression. Our consortium brings together leading experts in glycoscience, microbiology, cancer biology and immunology, structural biology, bioinformatics and translational research.

With nine academic and five industrial partners, one oncology center and an international network, GlyCaBiota provides complementary expertise, unique tools and clinical connections to train 15 doctoral candidates (DCs). The combination of excellent interdisciplinary science, industry know-how and clinical perspective covers the entire pipeline from fundamental discoveries to innovative solutions. DCs will gain cutting-edge scientific and transferable skills, positioning them for impactful careers across academia, industry and healthcare.

GlyCaBiota will create a critical mass of researchers capable of integrating glycoscience and microbiome research to tackle key challenges in CRC. By deciphering glycan-mediated interactions, GlyCaBiota will expand fundamental knowledge and strengthen European innovation capacity, enabling future development of precision diagnostics and therapeutic strategies for CRC.

Topics

Who is involved

OrganisationCityCountryRole
Universidade Nova De LisboaLisboaPortugalCoordinator
Canadian Glycomics NetworkEdmontonCanadaAssociatedpartner
Sib Swiss Institute of BioinformaticsGenfSwitzerlandParticipant
Glycodisplay ApsKobehavnDenmarkAssociatedpartner
Kobenhavns UniversitetKobenhavnDenmarkParticipant
Adaptam Therapeutics SLSan SebastianSpainAssociatedpartner
Asociacion Centro De Investigacion Cooperativa En Biociencias Cic BioguneDerio VizcayaSpainParticipant
Universidad Del Pais Vasco/ Euskal Herriko UnibertsitateaLeioaSpainAssociatedpartner
Centre National De La Recherche Scientifique CNRSParisFranceParticipant
Universite Grenoble AlpesGrenobleFranceAssociatedpartner
Universita Degli Studi Di Napoli Federico IiNapoliItalyParticipant
Academisch Ziekenhuis LeidenLeidenNetherlandsParticipant
GlycoTherapeutics B.V.NijmegenNetherlandsParticipant
Stichting Radboud UniversiteitNijmegenNetherlandsAssociatedpartner
Instituto Portugues De Oncologia Do Porto Francisco Gentil, EpePortoPortugalAssociatedpartner
Nzytech LdaLisboaPortugalParticipant
Imperial College of Science Technology and MedicineLondonUnited KingdomParticipant
Ludger LimitedAbingdonUnited KingdomParticipant
Quadram Institute BioscienceNorwichUnited KingdomParticipant
University of East AngliaNorwichUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI